Evaluation of the Ambulatory Medical Assistance Nurse Program in Chronic Lymphocytic Leukemia
NCT ID: NCT05350826
Last Updated: 2023-09-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
450 participants
INTERVENTIONAL
2023-04-13
2025-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tolerance and Resistance to Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL
NCT03502876
Prospective Study on the Feasibility of Plasma FLT3-Ligand Assay to Achieve a First Estimate of Its Prognostic Value on the Outcome of Patients Treated Intensively for Acute Leukemia
NCT02693899
Monocentric Phase 1 Study With Escalation of Doses of Tocilizumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients With Acute Myeloblastic Leukemia (AML)
NCT04547062
CLL Therapy Approaches in Russia
NCT05140369
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05105841
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ambulatory medical assistance
Patient benefiting from the ambulatory medical assistance nurse program in addition to conventional care for patients chronic lymphoid leukemia under targeted therapy
Ambulatory medical assistance
Ambulatory medical assistance is a patient-empowerment program and consists to programmed phone calls (bi-monthly for the first 6 months then monthly for the following 6 months) delivered by an oncology nurse, in link with the hematologist.
Conventional care
Patient benefiting from conventional care for patients chronic lymphoid leukemia under targeted therapy
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ambulatory medical assistance
Ambulatory medical assistance is a patient-empowerment program and consists to programmed phone calls (bi-monthly for the first 6 months then monthly for the following 6 months) delivered by an oncology nurse, in link with the hematologist.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with chronic lymphoid leukemia and starting treatment with targeted therapy: ibrutinib, venetoclax or acalabrutinib, alone or in combination with obinutuzumab or rituximab in 1L or R/R according to the indications of the Marketing Authorization.
* Be able to understand the objective and the constraints related to the research
* Patient having signed the consent form
* Patient with Social Security affiliation or equivalent
* Person able to speak on the phone
Exclusion Criteria
* Pregnant women
* Patients under judicial protection
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Toulouse
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Loïc YSEBAERT, MD, PhD
Role: STUDY_DIRECTOR
University Hospital, Toulouse
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CH Sud Réunion
Saint-Pierre, ILE de LA Reunion, France
CHU d'Angers
Angers, , France
CHU DE BREST Hôpital A.Morvan
Brest, , France
Hôpital Estaing
Clermont-Ferrand, , France
CHRU Dijon
Dijon, , France
CH du Mans
Le Mans, , France
Centre Hospitalier Lyon sud
Lyon, , France
Centre Léon Bérard
Lyon, , France
Hôpital Emile MULLER
Mulhouse, , France
CHRU de Nancy
Nancy, , France
Institut de Cancérologie du Gard
Nîmes, , France
Hôpital Saint-Louis
Paris, , France
CHU de Reims- Hôpital R.Debré
Reims, , France
CHU de RENNES
Rennes, , France
Hôpital Bretonneau
Tours, , France
CH Bretagne Atlantique Vannes
Vannes, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Hugo LEGENDRE, MD
Role: primary
Aline CLAVERT, MD
Role: primary
Hussam SAAD, MD
Role: primary
Romain GUIZEZ, PhD
Role: primary
Cédric ROSSI, MD
Role: primary
Kamel LARIBI, MD
Role: primary
Emmanuelle FERRANT, MD
Role: primary
Anne-Sophie MICHALLET, MD
Role: primary
Bernard DRENOU, MD
Role: primary
Pierre FEUGIER, PhD
Role: primary
Eric JOURDAN, MD
Role: primary
Catherine THIEBLEMONT, MD
Role: primary
Anne QUINQUENEL, MD
Role: primary
Sophie DE GUIBERT, MD
Role: primary
Caroline DARTIGEAS, MD
Role: primary
Mélanie MERCIER, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RC31/21/0340
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.